ReviewFrontiers in immunology2023
Cardiovascular involvement in Epstein-Barr virus infection.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Causal associations between antibody-mediated immune responses to infectious agents and cardiovascular inflammatory diseases: A Mendelian randomization study based on UK Biobank and FinnGen.Human vaccines & immunotherapeutics · 2026Article
- Acute Myocarditis: From Pathophysiology to Risk-Stratified Management-A Clinical Review.European journal of clinical investigation · 2026Review
- Post-viral myocarditis.Heart failure reviews · 2026Review
- The Bacterial, Viral, and Microbiome Contributions in Cardiovascular Diseases: A Narrative Review.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026Review
- Epstein-barr virus super-infection is associated with increased severity of hemorrhagic fever with renal syndrome.BMC infectious diseases · 2026Article
- Cardiovascular complications in chronic active Epstein-Barr virus infection: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Epstein-Barr virus reactivation triggers selective IL-6/IL-10 axis inflammation and CD3Frontiers in immunology · 2026Article
- Article
- Article
- Multifocal osteochondromatous proliferation and paraneoplastic hematologic dyscrasia in the context of latent Epstein-Barr virus reactivation: a case of oncologic and infectious pathophysiology.Skeletal radiology · 2025Article
- Causal effects of antibody-mediated immune responses on myocarditis: A two-sample Mendelian randomization study.Medicine · 2025Article
- The complex diagnosis of post-dialysis fever: a case report and literature review of infective endocarditis in a dialysis patient.BMC nephrology · 2025Review
- Non-Traditional Cardiovascular Risk Factors: Tailored Assessment and Clinical Implications.Journal of cardiovascular development and disease · 2025Review
- Acute Kidney Injury and Viral Myocarditis Secondary to Acute Epstein-Barr Virus Infection.Cureus · 2025Article
- Review
- Sinus arrest and syncope in a young patient with Epstein-Barr virus infection: a case report.European heart journal. Case reports · 2025Article
- When viral myocarditis meets thrombosis tendency: deep analysis of a complex case report.Frontiers in cardiovascular medicine · 2025Article
- Complete Heart Block: A Rare Initial Presentation of Epstein-Barr Virus-Induced Myocarditis.Cureus · 2025Article
- Cancer molecular subtyping using limited multi-omics data with missingness.PLoS computational biology · 2024Article
- Epstein-Barr Virus (EBV)-Associated Myopericarditis Provoking Severe Heart Failure in an Immunocompetent Young Male.Cureus · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular involvement is an uncommon but severe complication of Epstein-Barr virus (EBV) infection caused by direct damage and immune injury. Recently, it has drawn increasing attention due to its dismal prognosis. It can manifest in various ways, including coronary artery dilation (CAD), coronary artery aneurysm (CAA), myocarditis, arrhythmias, and heart failure, among others. If not treated promptly, cardiovascular damage can progress over time and even lead to death, which poses a challenge to clinicians. Early diagnosis and treatment can improve the prognosis and reduce mortality. However, there is a lack of reliable large-scale data and evidence-based guidance for the management of cardiovascular damage. Consequently, in this review, we attempt to synthesize the present knowledge of cardiovascular damage associated with EBV and to provide an overview of the pathogenesis, classification, treatment, and prognosis, which may enhance the recognition of cardiovascular complications related to EBV and may be valuable to their clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.